Brepocitinib Overview & RVT-3101 Update
Forward-Looking Statements
Forward-Looking Statements
This presentation includes forward-looking statements that are subject to substantial risks
and uncertainties that could cause actual results to differ materially from those expressed
or implied by such statements. All statements other than statements of historical facts
contained in this presentation, including statements regarding our future results of
operations and financial position, business strategy, research and development plans, the
anticipated timing, costs, design and conduct of our ongoing and planned preclinical
studies and clinical trials for our products and product candidates, including the
information presented in this presentation with respect to RVT-3101 and the potential for
RVT-3101 to improve the treatment of Ulcerative Colitis (UC) and Crohn's Disease (CD) and
to be a first-in-class agent, any commercial potential of our product candidates and the
receipt of proceeds from the expected sale of the Myovant top-up shares to Sumitomo
Pharma, are forward-looking statements.
These forward-looking statements are based upon the current expectations and beliefs of
our management as of the date of this presentation, and are subject to certain risks and
uncertainties that could cause actual results to differ materially from those described in
the forward-looking statements. Although we believe that our plans, intentions,
expectations and strategies as reflected in or suggested by those forward-looking
statements are reasonable, we can give no assurance that the plans, intentions,
expectations or strategies will be attained or achieved. Furthermore, actual results may
differ materially from those described in the forward-looking statements. The interim data
presented here for RVT-3101 is from the induction period of the TUSCANY-2 study and is
based on an interim analysis of key efficacy and safety data, and such data may change
following completion of the clinical trial and may not accurately reflect the complete
results of the TUSCANY-2 study.
Although we believe that our plans, intentions, expectations and strategies as reflected in
or suggested by those forward-looking statements are reasonable, we can give no
assurance that the plans, intentions, expectations or strategies will be attained or
achieved. Furthermore, actual results may differ materially from those described in the
forward-looking statements and will be affected by a number of risks, uncertainties and
assumptions, including, but not limited to, those risks set forth in the sections captioned
"Risk Factors" and "Forward-Looking Statements" of our filings with the U.S. Securities and
Exchange Commission, available at www.sec.gov and investor.roivant.com. We operate in
a very competitive and rapidly changing environment in which new risks emerge from
time to time. These forward-looking statements are based upon the current expectations
and beliefs of our management as of the date of this presentation, and are subject to
certain risks and uncertainties that could cause actual results to differ materially from
those described in the forward-looking statements. Except as required by applicable law,
we assume no obligation to update publicly any forward-looking statements, whether as
a result of new information, future events or otherwise.
This presentation includes data, results and attributes for RVT-3101 and certain other
products and product candidates generated from separate, independent studies and that
do not come from head-to-head analysis. Differences exist between study or trial designs
and subject characteristics and caution should be exercised when comparing data across
studies. Data regarding other products and product candidates is based on publicly
available information.
Disclaimer
Today's discussions and presentation are intended for the investor community only; they
are not intended to promote the product candidates referenced herein or otherwise
influence healthcare prescribing decisions.
roivant
For investor audiences only
2View entire presentation